Euronext Eurozone SBT 15 NR Decrement 5 (ZSN5D) News

Invivyd to Participate at the H.C. Wainwright 2nd Annual BioConnect Investor Conference

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Form S-8 - Securities to be offered to employees in employee benefit plans

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Invivyd Reports First Quarter 2024 Financial Results and Recent Business Highlights

Launched PEMGARDA™ in the U.S. for COVID-19 pre-exposure prophylaxis (PrEP) in certain adults and adolescents...

Form 8-K - Current report

Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback

Pathway leverages immunobridging approach via serum virus neutralizing antibody (sVNA) titers enabled by prior...

Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights

WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position

Improvements realized through comprehensive resource realignment ensuring robust investment in the commercial...

Invivyd Receives Healthcare Common Procedure Coding System (HCPCS) Reimbursement Codes from the U.S. Centers for Medicare & Medicaid Services (CMS) Covering PEMGARDA™

Product-specific Q Code (Q0224) facilitates product reimbursement for PEMGARDA; corresponding M Code (M0224...

Invivyd Announces CEO Transition

WALTHAM, Mass., April 12, 2024 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a biopharmaceutical company...

Invivyd Provides PEMGARDA™ Launch Update and Announces 2024 Net Product Revenue Guidance in the Range of $150 Million to $200 Million

PEMGARDA now commercially available in the U.S. for pre-exposure prophylaxis (PrEP) of COVID-19 in certain...

Invivyd Reports Full Year 2023 Financial Results and Recent Business Highlights

Received emergency use authorization for PEMGARDA™, a monoclonal antibody (mAb) authorized in the U.S. for...

Invivyd Announces Interim Exploratory Data on VYD222 from Ongoing CANOPY Clinical Trial

Analysis of secondary endpoint of symptomatic COVID-19 events in CANOPY is unrelated to regulatory filing or...

Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19

PEMGARDA (pemivibart) is authorized in the U.S. for PrEP of COVID-19 in certain adults and adolescents with...